What to know about TriSalus Life Sciences Inc (TLSI)’s sales and margins

Nora Barnes

TriSalus Life Sciences Inc [TLSI] stock prices are up 2.86% to $6.47 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TLSI shares have gain 41.27% over the last week, with a monthly amount glided 31.77%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 17, 2024, and set its price target to $10. On November 11, 2024, ROTH MKM initiated with a Buy rating and assigned a price target of $11 on the stock. Northland Capital started tracking the stock assigning a Outperform rating and suggested a price target of $12.50 on October 25, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $10 as its price target on September 16, 2024. Canaccord Genuity started tracking with a Buy rating for this stock on May 30, 2024, and assigned it a price target of $12.

The stock price of TriSalus Life Sciences Inc [TLSI] has been fluctuating between $3.42 and $6.40 over the past year. Currently, Wall Street analysts expect the stock to reach $10.5 within the next 12 months. TriSalus Life Sciences Inc [NASDAQ: TLSI] shares were valued at $6.47 at the most recent close of the market. An investor can expect a potential return of 62.29% based on the average TLSI price forecast.

Analyzing the TLSI fundamentals

The TriSalus Life Sciences Inc [NASDAQ:TLSI] reported sales of 40.21M for trailing twelve months, representing a surge of 57.38% . Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.78%, Pretax Profit Margin comes in at -0.98%, and Net Profit Margin reading is -1.74%. To continue investigating profitability, this company’s Return on Assets is posted at -1.92, Equity is 2.63 and Total Capital is -1.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.28.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.12 points at the first support level, and at 5.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.66, and for the 2nd resistance point, it is at 6.86.

Ratios To Look Out For

It’s worth pointing out that TriSalus Life Sciences Inc [NASDAQ:TLSI]’s Current Ratio is 3.05. Further, the Quick Ratio stands at 2.75, while the Cash Ratio is 2.08. Considering the valuation of this stock, the price to sales ratio is 8.04.

Transactions by insiders

Recent insider trading involved Cox Bryan F., Chief of Research, that happened on May 19 ’25 when 4764.0 shares were sold. Chief of Clinical Operations, Devlin Jodi completed a deal on May 19 ’25 to sell 4764.0 shares. Meanwhile, Chief Commercial Officer Marshak Richard sold 6597.0 shares on May 19 ’25.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.